Flt3 tyrosine kinase inhibitors (DCAM)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameFlt3 tyrosine kinase inhibitors (DCAM)
Drug Alias NameSymadex follow-on compounds (Antisoma)Dendritic cell autoimmune modulators (Antisoma)Flt3 Tyrosine Kinase Inhibitor Program (Antisoma)DCAMs (Antisoma)DCAM-3 +[6] 
ClassificationSmall molecules
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsTopoisomerase II inhibitorsDNA topoisomerase I inhibitors
TargetsTopoisomerase IITyrosine-protein kinase receptor FLT3DNA topoisomerase I
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAntisoma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDCAM Pharma IncAntisoma
Active IndicationsN/A
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A